Tech Company M&A Transactions
Transave Acquisition
Operating out of Monmouth Junction, Transave was acquired by Insmed. The acquisition price was $44 million.
Transaction Overview
Company Name
Acquired By
Announced On
12/2/2010
Transaction Type
M&A
Amount
$44,000,000
M&A Terms
Under the terms of the merger agreement, Insmed acquired all of the outstanding capital stock of Transave and paid off all of Transave's $7.8 million debt, for approximately 25.9 million shares of Insmed common stock, and approximately 91.7 million shares of Insmed Series B Conditional Convertible Preferred Stock with a stated value of $0.7114 per share and cash consideration of $561,280.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
11 Deer Park Drive 117
Monmouth Junction, NJ 08852
USA
Monmouth Junction, NJ 08852
USA
Phone
Website
Email Address
Not Recorded
Overview
TRANSAVE is a biotechnology company whose mission is to improve the treatment of serious lung diseases through the development of novel, site-specific liposomal drug products.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Timothy Whitten
Chief Financial Officer
Michio Soga
Chief Medical Officer
Renu Gupta
Chief Technical Officer
Walter Perkins
Vice President
Eric Dadey
VP - Operations
Nicholas Gurreri
Browse more venture capital transactions:
Prev: 12/2/2010: PhaseBio Pharmaceuticals venture capital transaction
Next: 12/2/2010: Strobe venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to report on tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs